Antiplatelet Therapy for Postdischarge Medical Management of Acute Coronary Syndrome

American Journal of Medicine

Volumn 121, Issue 3, 2008, Pages 171-178

  Faxon, David ^a   Brown, Marie ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndrome; Aspirin; Clopidogrel; Non ST segment elevation myocardial infarction; NSTEMI; ST segment elevation myocardial infarction; STEMI; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; WARFARIN;

ACUTE CORONARY SYNDROME; BLEEDING; DRUG ELUTING STENT; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HEALTH CARE QUALITY; HOSPITAL DISCHARGE; HUMAN; LIFESTYLE MODIFICATION; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION;

ACUTE CORONARY SYNDROME; PATIENT DISCHARGE; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 40049093909     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.09.026     Document Type: Review

References (46)

1. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
2. Taneja A.K., Collinson J., Flather M.D., et al. Mortality following non-ST elevation acute coronary syndrome: 4 years follow-up of the PRAIS UK Registry (Prospective Registry of Acute Ischaemic Syndromes in the UK). Eur Heart J 25 (2004) 2013-2018
3. Baigent C., Collins R., Appleby P., et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 316 (1998) 1337-1343
4. Bhatt D.L., and Topol E.J. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 148 (2004) 263-268
5. Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
6. Steinhubl S.R., and Moliterno D.J. The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drugs 5 (2005) 399-408
7. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110 (2004) e82-e292
8. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 136 (2002) 157-160
9. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
10. Peters R.J., Mehta S.R., Fox K.A., et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108 (2003) 1682-1687
11. Harrington R.A., Becker R.C., Ezekowitz M., et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 513S-548S
12. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116 (2007) e148-e304
13. Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
14. Grines C.L., Bonow R.O., Casey Jr. D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Dent Assoc 138 (2007) 652-655
15. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40 (2002) 1366-1374
16. U.S. Food and Drug Administration. FDA statement on coronary drug-eluting stents (September 14, 2006), Vol 2007 (2006)
17. Lecompte T., and Hardy J.F. Antiplatelet agents and perioperative bleeding. Can J Anaesth 53 (2006) S103-S112
18. Ferguson J.J. The role of oral antiplatelet agents in atherothrombotic disease. Am J Cardiovasc Drugs 6 (2006) 149-157
19. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
20. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
21. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
22. Steinhubl S.R., Berger P.B., Mann III J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
23. Zeymer U., Gitt A.K., Junger C., et al. Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. Eur Heart J 27 (2006) 2661-2666
24. Hodgson J.M., Stone G.W., Michael Lincoff A., et al. Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the society for cardiovascular angiography and interventions drug-eluting stent task force. Catheter Cardiovasc Interv 69 (2007) 327-333
25. Ong A.T.L., McFadden E.P., Regar E., et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45 (2005) 2088-2092
26. Park D.W., Park S.W., Park K.H., et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 98 (2006) 352-356
27. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
28. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
29. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
30. U.S. Food and Drug Administration. Update to FDA statement on coronary drug-eluting stents, Vol 2007.
31. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2006) e166-e286
32. Bhatt D.L., Steg P.G., Ohman E.M., et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295 (2006) 180-189
33. CRUSADE National Quality Initiative, Vol 2007.
34. Spencer F., Scleparis G., Goldberg R.J., et al. Decade-long trends (1986 to 1997) in the medical treatment of patients with acute myocardial infarction: a community-wide perspective. Am Heart J 142 (2001) 594-603
35. Stafford R.S., and Radley D.C. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol 41 (2003) 56-61
36. Kramer J.M., Fetterolf D., Charde J.P., et al. National evaluation of long-term adherence to beta-blocker therapy after acute myocardial infarction in patients with commercial health insurance. J Am Coll Cardiol 43 (2004) 415a-416a
37. Steinberg B.A., Steg P.G., Bhatt D.L., et al. Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry). Am J Cardiol 99 (2007) 1212-1215
38. Hirsch A.T., Bhatt D.L., McBride P.E., et al. Global risk factors and treatment intensity in elderly patients with atherosclerosis: the experience of the international REACH registry. J Am Coll Cardiol 47 (2006) 168A
39. Mehta R.H., Roe M.T., Chen A.Y., et al. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med 166 (2006) 2027-2034
40. CRUSADE National Quality Initiative. 2006 CRUSADE 2nd Quarter Results, Vol 2007.
41. Calvin J.E., Roe M.T., Chen A., et al. Higher mortality and less evidence-based therapies among Medicaid-insured patients with high-risk acute coronary syndromes: Results from CRUSADE. J Am Coll Cardiol 43 (2004) 413a
42. LaBresh K.A., Ellrodt A.G., Gliklich R., et al. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med 164 (2004) 203-209
43. Mehta R.H., Montoye C.K., Gallogly M., et al. Improving quality of care for acute myocardial infarction: the Guidelines Applied in Practice (GAP) Initiative. JAMA 287 (2002) 1269-1276
44. Qureshi A.I., Suri M.F., Guterman L.R., and Hopkins L.N. Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med 161 (2001) 1621-1628
45. Pearson T.A., Blair S.N., Daniels S.R., et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106 (2002) 388-391
46. CRUSADE National Quality Initiative: MAINTAIN CRUSADE: Medication Applied and Sustained Over Time. A Longitudinal Follow-Up Study of the CRUSADE Quality Improvement Initiative, Vol 2007.